DOP2020000197A - Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos - Google Patents
Compuestos inhibidores de rip1 y métodos para preparar y usar los mismosInfo
- Publication number
- DOP2020000197A DOP2020000197A DO2020000197A DO2020000197A DOP2020000197A DO P2020000197 A DOP2020000197 A DO P2020000197A DO 2020000197 A DO2020000197 A DO 2020000197A DO 2020000197 A DO2020000197 A DO 2020000197A DO P2020000197 A DOP2020000197 A DO P2020000197A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- rip1
- preparing
- methods
- kinase
- inhibiting compounds
- Prior art date
Links
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente, se desvelan compuestos inhibidores de quinasa, tales como compuestos inhibidores de la proteína quinasa 1 que interactúa con el receptor (RIP1), así como composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, las composiciones farmacéuticas y/o las combinaciones desvelados se pueden usar para inhibir una quinasa RIP1 in vivo o ex vivo y también pueden tratar o prevenir una enfermedad o afección asociada a la quinasa, en particular, una enfermedad o afección asociada a la RIP1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666452P | 2018-05-03 | 2018-05-03 | |
| PCT/US2019/030473 WO2019213445A1 (en) | 2018-05-03 | 2019-05-02 | Rip1 inhibitory compounds and methods for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2020000197A true DOP2020000197A (es) | 2021-04-30 |
Family
ID=66554488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2020000197A DOP2020000197A (es) | 2018-05-03 | 2020-11-02 | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10975064B2 (es) |
| EP (1) | EP3788045B1 (es) |
| JP (1) | JP7379467B2 (es) |
| KR (1) | KR20210006407A (es) |
| CN (1) | CN112384510A (es) |
| AU (1) | AU2019262142A1 (es) |
| BR (1) | BR112020022423A2 (es) |
| CA (1) | CA3099018A1 (es) |
| CL (1) | CL2020002840A1 (es) |
| CO (1) | CO2020015153A2 (es) |
| CR (1) | CR20200582A (es) |
| CY (1) | CY1126152T1 (es) |
| DK (1) | DK3788045T3 (es) |
| DO (1) | DOP2020000197A (es) |
| EA (1) | EA202092581A1 (es) |
| EC (1) | ECSP20077518A (es) |
| ES (1) | ES2947446T3 (es) |
| FI (1) | FI3788045T3 (es) |
| HR (1) | HRP20230909T1 (es) |
| HU (1) | HUE062277T2 (es) |
| IL (1) | IL278416B2 (es) |
| JO (1) | JOP20200277A1 (es) |
| LT (1) | LT3788045T (es) |
| MA (1) | MA52492B1 (es) |
| MD (1) | MD3788045T2 (es) |
| MX (1) | MX2020011622A (es) |
| PE (1) | PE20210414A1 (es) |
| PH (1) | PH12020551848A1 (es) |
| PL (1) | PL3788045T3 (es) |
| PT (1) | PT3788045T (es) |
| RS (1) | RS64418B1 (es) |
| SG (1) | SG11202010913PA (es) |
| SI (1) | SI3788045T1 (es) |
| WO (1) | WO2019213445A1 (es) |
| ZA (1) | ZA202007487B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE062277T2 (hu) | 2018-05-03 | 2023-10-28 | Rigel Pharmaceuticals Inc | RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása |
| CN112368278A (zh) | 2018-05-03 | 2021-02-12 | 里格尔药品股份有限公司 | Rip1抑制性化合物以及制备和使用其的方法 |
| MX2022002719A (es) * | 2019-09-06 | 2022-08-10 | Rigel Pharmaceuticals Inc | Inhibidores heterociclicos de la quinasa rip1. |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| BR112022002378A2 (pt) | 2019-09-06 | 2022-06-14 | Rigel Pharmaceuticals Inc | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos |
| JP2022550099A (ja) | 2019-09-27 | 2022-11-30 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| CN115298184A (zh) * | 2019-11-07 | 2022-11-04 | 里格尔药品股份有限公司 | 杂环rip1抑制化合物 |
| CN114981248A (zh) * | 2019-11-26 | 2022-08-30 | 德州大学系统董事会 | 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| CN115867557A (zh) * | 2021-05-14 | 2023-03-28 | 中国医药研究开发中心有限公司 | 氮杂卓类稠环化合物及其医药用途 |
| CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
| WO2023076133A1 (en) * | 2021-10-27 | 2023-05-04 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
| WO2023119210A1 (ko) * | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| IE66203B1 (en) | 1989-12-04 | 1995-12-13 | Searle & Co | System for transdermal albuterol administration |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| CA2123809A1 (en) | 1991-12-18 | 1993-06-24 | Debra L. Wilfong | Multilayered barrier structures |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| EP3034494A1 (en) | 2007-08-15 | 2016-06-22 | President and Fellows of Harvard College | Heterocyclic inhibitors of necroptosis |
| TWI638815B (zh) | 2013-02-15 | 2018-10-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（一） |
| EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| EP3182974A1 (en) | 2014-08-21 | 2017-06-28 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| EP3256467A1 (en) | 2015-02-13 | 2017-12-20 | GlaxoSmithKline Intellectual Property Management Limited | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide |
| MY192762A (en) | 2015-07-02 | 2022-09-07 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
| DK3362449T3 (da) | 2015-10-13 | 2021-07-19 | Inst Nat Sante Rech Med | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
| JP6754772B2 (ja) | 2015-10-23 | 2020-09-16 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| WO2017136727A2 (en) | 2016-02-05 | 2017-08-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CA3052767A1 (en) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CN112368278A (zh) | 2018-05-03 | 2021-02-12 | 里格尔药品股份有限公司 | Rip1抑制性化合物以及制备和使用其的方法 |
| HUE062277T2 (hu) | 2018-05-03 | 2023-10-28 | Rigel Pharmaceuticals Inc | RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása |
| CA3104757A1 (en) | 2018-06-26 | 2020-01-02 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| MX2022002719A (es) | 2019-09-06 | 2022-08-10 | Rigel Pharmaceuticals Inc | Inhibidores heterociclicos de la quinasa rip1. |
| BR112022002378A2 (pt) | 2019-09-06 | 2022-06-14 | Rigel Pharmaceuticals Inc | Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2019
- 2019-05-02 HU HUE19724662A patent/HUE062277T2/hu unknown
- 2019-05-02 EA EA202092581A patent/EA202092581A1/ru unknown
- 2019-05-02 IL IL278416A patent/IL278416B2/en unknown
- 2019-05-02 PT PT197246622T patent/PT3788045T/pt unknown
- 2019-05-02 JP JP2021510283A patent/JP7379467B2/ja active Active
- 2019-05-02 AU AU2019262142A patent/AU2019262142A1/en active Pending
- 2019-05-02 DK DK19724662.2T patent/DK3788045T3/da active
- 2019-05-02 HR HRP20230909TT patent/HRP20230909T1/hr unknown
- 2019-05-02 FI FIEP19724662.2T patent/FI3788045T3/fi active
- 2019-05-02 MD MDE20210214T patent/MD3788045T2/ro unknown
- 2019-05-02 SI SI201930550T patent/SI3788045T1/sl unknown
- 2019-05-02 MA MA52492A patent/MA52492B1/fr unknown
- 2019-05-02 CN CN201980045150.5A patent/CN112384510A/zh active Pending
- 2019-05-02 LT LTEPPCT/US2019/030473T patent/LT3788045T/lt unknown
- 2019-05-02 JO JOP/2020/0277A patent/JOP20200277A1/ar unknown
- 2019-05-02 KR KR1020207034544A patent/KR20210006407A/ko unknown
- 2019-05-02 BR BR112020022423-5A patent/BR112020022423A2/pt unknown
- 2019-05-02 US US16/402,103 patent/US10975064B2/en active Active
- 2019-05-02 MX MX2020011622A patent/MX2020011622A/es unknown
- 2019-05-02 EP EP19724662.2A patent/EP3788045B1/en active Active
- 2019-05-02 WO PCT/US2019/030473 patent/WO2019213445A1/en active Application Filing
- 2019-05-02 CA CA3099018A patent/CA3099018A1/en active Pending
- 2019-05-02 SG SG11202010913PA patent/SG11202010913PA/en unknown
- 2019-05-02 PL PL19724662.2T patent/PL3788045T3/pl unknown
- 2019-05-02 RS RS20230648A patent/RS64418B1/sr unknown
- 2019-05-02 ES ES19724662T patent/ES2947446T3/es active Active
- 2019-05-02 CR CR20200582A patent/CR20200582A/es unknown
- 2019-05-02 PE PE2020001796A patent/PE20210414A1/es unknown
-
2020
- 2020-11-02 DO DO2020000197A patent/DOP2020000197A/es unknown
- 2020-11-02 CL CL2020002840A patent/CL2020002840A1/es unknown
- 2020-11-03 PH PH12020551848A patent/PH12020551848A1/en unknown
- 2020-12-01 CO CONC2020/0015153A patent/CO2020015153A2/es unknown
- 2020-12-01 ZA ZA2020/07487A patent/ZA202007487B/en unknown
- 2020-12-01 EC ECSENADI202077518A patent/ECSP20077518A/es unknown
-
2021
- 2021-03-23 US US17/210,261 patent/US11919890B2/en active Active
-
2023
- 2023-07-25 CY CY20231100349T patent/CY1126152T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000169A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| DOP2022000051A (es) | Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos | |
| DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| CO2022014137A2 (es) | Inhibidores de rip1k | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CL2019002810A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos. | |
| CO2023000051A2 (es) | Inhibidores de rip1k | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CU20160157A7 (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
| CO2023012077A2 (es) | Inhibidores heterocíclicos de la cinasa rip1 |